Owen Dempsey is an accomplished executive and serial entrepreneur with over 25 years of experience building and advising businesses in the life sciences and healthcare. A founder or CEO of successful start-ups including Endogen, Perbio Science and SRU Biosystems, he focuses today on consulting to both large organizations and start-ups on innovation, business strategy, financing and strategic partnering.
Dempsey has run private and public companies ranging in size from start-ups to global businesses. He is experienced with tackling the challenges that face growing enterprises, from company strategy to all stages of venture finance, corporate partnering, acquisitions, M&A process, as well as NASDAQ and foreign listings. Dempsey brings with him real world leadership experience, their lessons and wisdom. He brings a genuine love of working with talented teams to identify and achieve lofty, demanding goals.
As the CEO of SRU Biosystems, a new drug discovery platform company, Dempsey assembled an award-winning team to launch a revolutionary screening platform and to forge successful partnerships with pharma and biotech. He is currently a board member or advisor to a several life science companies in the USA and Europe. His recent focus has been adapting to the rapid changes in life science, pharmaceutical and healthcare markets.
Dempsey has worked with senior managers at leading pharma and biotech organizations as well as with founders and entrepreneurs in fast-growing ventures to deliver results and meet crtitical goals.
Prior to leading SRU Biosystems and joining Sagebrook Partners, Mr. Dempsey co-founded and served as CEO of Endogen, Inc., a specialty life sciences company providing novel biologics for research and drug discovery. Endogen became recognized globally in its field, with manufacturing, sales and distrbution in over forty countries. The company merged in 1999 with a division of Perstorp International to form Perbio Science AB. Owen stayed with the business following the merger, and led several product line and company integrations including Pierce Chemical, acquired or licensed new technologies, and participated in building the Perbio Science business to over $240 million in revenues before it was acquired in 2003 by Fisher Scientific (now Thermo Fisher) for $738 million. Owen is a past Board Director of ALDA (the Analytical, Life Science and Diagnostics Association).
Mr. Dempsey holds a BA degree from Dartmouth College and MBA degree from Stanford University Graduate School of Business. After Stanford he worked at IMEDE (the International Management Development Institute) in Lausanne, Switzerland, focusing on business innovation and global markets. He is currently affiliated with the Harvard Innovation Lab, Stanford’s Center for Entrepreneurial Studies and as a mentor with the Dartmouth Entrepreneurial Network at Tuck Business School and Dartmouth Hitchcock Medical Center.
Sagebrook Partners, LLC
Cambridge, MA 02142
617 510 5810